Similarly, B1a Bregs (CD19+CD5+CD43+) have been described to use IL-10 to inhibit IFNγ and TNFα production by CD8+T cells thus negatively regulating tumour immunity against melanoma cells [49]. This evidence concerns the gene CD19 and neoplasm.